Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03327558 · ClinicalTrials.gov registry record · Phase 1
Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects
A Phase 1 study, sponsored by Bausch Health Americas.
- Completed
- Registry status
- Phase 1
- Development phase
- 60
- Enrollment target
NCT03327558 is a Phase 1 study that has completed, run by Bausch Health Americas. The registered enrollment target is 60 participants.
The verdict
NCT03327558, a Phase 1 study, has completed, sponsored by Bausch Health Americas.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 60 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate and compare the bioavailability of mesalamine
Interventions
- DRUG Apriso 0.375G ER CAP
- DRUG APRISO 375 mg extended-release capsules
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 60 participants |
| Start Date | 2017-05-15 |
| Est. Completion | 2017-08-18 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03327558
The ClinicalTrials.gov registry entry for NCT03327558 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bausch Health Americas, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Apriso 0.375G ER CAP is the first listed.
NCT03327558 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03327558 about?
NCT03327558 is a clinical study titled "Randomized,Study of APRISO 375 mg Versus the Approved APRISO 375 mg Capsules in Healthy Male and Female Subjects". The objective of this study is to evaluate and compare the bioavailability of mesalamine
What is the current status of trial NCT03327558?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2017-05-15. Estimated completion is 2017-08-18.
What interventions are being tested in trial NCT03327558?
The interventions under investigation include: Apriso 0.375G ER CAP (DRUG), APRISO 375 mg extended-release capsules (DRUG).
Who is sponsoring clinical trial NCT03327558?
This trial is sponsored by Bausch Health Americas, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.